About Pricing FAQs Providers Trials Blog

Back to your record

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Breast Cancer Clinical Trials in Dallas | 559 Studies

Clinical Trials Breast CancerDallas

Breast Cancer Clinical Trials in Dallas

Find 559 clinical trials for breast cancer near Dallas, Texas. Connect with research centers in your area.

All Breast Cancer trials nationwide All trials in Dallas

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 381-400 of 559 trials

Active not recruitingStudy of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) versus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant…NCT03725059·Daphne, Alabama and 243 others

Breast Cancer Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

Active not recruitingPhase II Multi-center Trial Evaluating 5 Fraction Stereotactic Partial Breast Irradiation Using GammapodStereotactic radiation has been implemented more than 3 decades ago, initially to radiate benign and later malignant tumors within the brain.NCT03581136·Baltimore, Maryland and 1 other

CompletedCyberknife® Partial Breast Irradiation (PBI) for Early Stage Breast CancerBy using stereotactic body radiation therapy (SBRT) delivered with the Cyberknife system®, the current protocol attempts to mimic or improve the excellent local control rates seen…NCT01162200·Dallas, Texas and 1 other

CompletedStudy to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast CancerThis is a Phase 2, open-label, single arm, multicenter, 2-stage study of eribulin mesylate administered biweekly at 1.4 mg/m2 intravenously for the treatment of participants with…NCT02481050·Denver, Colorado and 11 others

UnknownStudy of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor MalignanciesStudy of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor MalignanciesNCT04913337·Los Angeles, California and 26 others

RecruitingA Study of LY4257496 in Participants With Cancer (OMNIRAY)The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in…NCT07114601·Duarte, California and 32 others

CompletedDaily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast CancerThis phase III, double-blind, placebo-controlled multinational study will assess the combination everolimus, vinorelbine, and trastuzumab compared to the combination vinorelbine…NCT01007942·Tucson, Arizona and 160 others

WithdrawnTest - Retest Reproducibility of 18F Fluoroestradiol (FES) PETThis study will formally address the hypothesis that FES-PET/CT measurement of ER expression predicts clinical benefit of first-line endocrine therapy in newly diagnosed ER+…NCT03065712·Dallas, Texas

TerminatedTesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBCCONTESSA 2 is a multinational, multicenter, Phase 2 study of tesetaxel in patients with HER2 negative, HR positive, locally advanced or metastatic breast cancer (LA/MBC) not…NCT03858972·Whittier, California and 24 others

RecruitingA Phase 1 Study of IM-1617 in Participants With Advanced CancerThis study will test the safety and effectiveness of a drug called IM-1617 in participants with solid tumors.NCT07578571·New Haven, Connecticut and 4 others

CompletedA Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast CancerThis randomized, double-blind, placebo-controlled, two-arm study will assess the safety and efficacy of pertuzumab in addition to chemotherapy plus trastuzumab as adjuvant therapy…NCT01358877·Scottsdale, Arizona and 545 others

Active not recruitingA Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the physician's choice of endocrine…NCT05306340·Anchorage, Alaska and 135 others

TerminatedStudy of AFP464 +/- Faslodex in ER + Breast CancerAFP464 is an investigational agent which may be effective in the treatment of cancer.NCT01233947·Dallas, Texas

CompletedA Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid TumorsThis will be a Phase 1, open label, 2-sequence, crossover study to establish the BE of the current commercial formulation (Generation 3.1 talazoparib capsules) to the proposed…NCT04672460·Encinitas, California and 30 others

RecruitingA Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in…NCT06312176·Chandler, Arizona and 258 others

CompletedTrastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]This study will compare DS-8201a to physician choice standard treatment. Participants must have HER2-low breast cancer that has been treated before.NCT03734029·Chandler, Arizona and 207 others

CompletedStudy to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid TumorsThe primary objective of the study is to determine the maximum tolerated dose of andecaliximab monotherapy and to evaluate the safety and tolerability of andecaliximab (formerly…NCT01803282·Birmingham, Alabama and 17 others

CompletedLS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast CancerThe aim of this Phase 1b/2 study is to investigate the safety, efficacy, and pharmacokinetics (PK) of a single dose of LS301-IT, a novel fluorescence imaging agent developed by…NCT05900986·Scottsdale, Arizona and 8 others

Active not recruitingCapivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast CancerPhase III, double-blind, randomised study assessing the efficacy of capivasertib + fulvestrant vs placebo + fulvestrant for the treatment of patients with locally advanced…NCT04305496·Gilbert, Arizona and 214 others

RecruitingStudy of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast CancerThis clinical trial is evaluating tucatinib in combination with Doxil in participants with human epidermal growth factor 2 positive (HER2+) locally advanced or metastatic breast…NCT05748834·Columbia, Maryland and 7 others

PreviousPage 20 of 28Next

Other Conditions in Dallas

Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma